View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 29, 2015updated 13 Jul 2022 10:48am

Lilly and Immunocore enter clinical trial collaboration for new melanoma treatment

Eli Lilly and Company and Immunocore have entered into an immunotherapy-based clinical trial collaboration to explore the utility of IMCgp100 in combination with galunisertib and merestinib to treat melanoma.

melanoma

Eli Lilly and Company and Immunocore have entered into an immunotherapy-based clinical trial collaboration to explore the utility of IMCgp100 in combination with galunisertib and merestinib to treat melanoma.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The deal is aimed at identifying combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas.

IMCgp100 is Immunocore’s lead T cell receptor-based investigational therapeutic, while galunisertib (LY2157299) is Lilly’s TGF beta R1 kinase inhibitor and merestinib (LY2801653) is a multi-kinase inhibitor.

"We are very pleased to be able to announce a second collaboration with Lilly after entering into a collaboration last year."

As part of the deal, the companies will conduct a Phase Ib/II clinical trial evaluating the safety and preliminary efficacy of IMCgp100 in combination with galunisertib in metastatic cutaneous melanoma.

They will also conduct a second Phase Ib/II trial evaluating the combination of IMCgp100 and merestinib to treat metastatic uveal melanoma.

Lilly will act as trial sponsor for these studies, which are expected to be initiated next year.

Both IMCgp100 and galunisertib are members of a new class of cancer treatments called immunotherapies, which are designed to improve the body’s own immune system in fighting cancer.

Immunocore chief executive officer Eliot Forster said: "We are very pleased to be able to announce a second collaboration with Lilly after entering into a collaboration last year.

"Combining our ImmTAC, IMCgp100 with Lilly’s galunisertib and merestinib has the potential to transform the treatment of metastatic cutaneous and uveal melanoma.

"Immunocore is committed to the development of IMCgp100 in metastatic uveal and cutaneous melanoma where there is such great unmet medical need."

In July 2014, the two firms entered into a co-discovery and co-development collaboration to research and potentially develop other novel T cell-based cancer therapies built on Immunocore’s ImmTAC platform.

Recently, Immunocore had reported clinical efficacy data in a Phase I/IIa trial with IMCgp100 in patients with advanced melanoma, as well as in the expansion cohort with uveal melanoma.

IMCgp100 mobilises mTCR Against Cancer molecules (ImmTAC), which are a new class of bi-specific biologic drugs based on T cell receptors (TCRs) with ultra-high affinity for intracellular and extracellular cancer targets.


Image: Molecular basis for melanoma cell motility. Photo: courtesy of Julio C. Valencia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena